生存分析からみた進行肝細胞癌に対するソラフェニブ投与例の検討

概要

論文の詳細を見る
We investigated the pretreatment factors that were associated with the outcome of patients with hepatocellular carcinoma (HCC) who received the administration of sorafenib. Survival rates were compared according to the initial treatment for HCC, Child-Pugh class, extrahepatic metastasis, portal vein invasion, AFP, AFP-L3, and PIVKA-II, in 26 HCC patients who were administered sorafenib. Univariate analysis revealed the state of portal vein invasion (≤Vp2 vs. ≥Vp3) as a factor that was associated patient survival (p=0.016). By multivariate analysis, the state of portal vein invasion (hazard ratio, 4.631; 95% confidence interval, 1.541-13.921; p=0.006) was selected as factors that affected patient survival. The present result shows that portal vein invasion of ≥Vp3 indicated poor outcome in patients with HCC treated by sorafenib.